| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.02 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |